T1	Participants 12 42	progressive supranuclear palsy
T2	Participants 103 139	progressive supranuclear palsy (PSP)
T3	Participants 446 519	PSP in two randomized double-blind, placebo controlled, crossover studies
T4	Participants 547 581	patients enrolled in these studies
